Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline plc : GSK presents phase lll data for lapatinib at San Antonio breast cancer symposium

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/09/2011 | 07:30am CET

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

Issued: Thursday 08 December 2011, London, UK

- Improvement in disease-free survival does not reach statistical significance in study of delayed adjuvant therapy with lapatinib (Tykerb or Tyverb) monotherapy in HER2 positive breast cancer.

Results from TEACH (Tykerb Evaluation After Chemotherapy) were presented today at the 2011 CRTC-AACR San Antonio Breast Cancer Symposium.  TEACH is a randomised, double-blind, placebo-controlled Phase III trial to evaluate the effects of lapatinib monotherapy when given to women who were diagnosed with HER2 positive breast cancer, received treatment excluding trastuzumab, and remained disease free.  The median time from diagnosis to study entry was 3 years. Use of lapatinib in the delayed adjuvant setting is investigational only and not approved by regulatory authorities anywhere in the world.  

The primary objective of the study was to compare disease-free survival (DFS) between women receiving lapatinib and those receiving placebo.  More than 3000 women who completed neo-adjuvant or adjuvant chemotherapy, did not receive trastuzumab and did not have evidence of disease were randomised to receive lapatinib or placebo for up to 12 months or until a DFS event, defined as objective disease recurrence, a second primary cancer, contralateral breast cancer  or death from any cause.  After a median follow up of 4 years, DFS events occurred in 13% of patients in the lapatinib arm and 17% of patients in the placebo arm of the trial (Hazard Ratio = 0.83 95% Confidence Interval, 0.70 to 1.00; stratified log-rank 2-sided p=0.053).  Therefore, although an improvement in disease-free survival in favor of lapatinib was observed, this result did not meet the prespecified criteria for statistical significance.

Serious adverse events were reported in 6% of the lapatinib arm and 5% of the placebo arm.  The rate of Grade 3 diarrhoea was 6% in the lapatinib arm and <1% in the placebo arm (no Grade 4 events).  The rate of Grade 3 rash was 5% in the lapatinib arm and <1% in the placebo arm.  There was one Grade 4 rash event in the lapatinib arm   Hepatobiliary adverse events of Grade 3/4 severity were reported in 2% of the lapatinib arm and <1% of the placebo arm.    

"Although we are disappointed that the improvement in disease-free survival with lapatinib monotherapy in TEACH did not reach statistical significance, lapatinib combination therapy remains an important treatment option for patients with metastatic Her2+ breast cancer whose disease has progressed on treatment with trastuzumab-based regimens," said Rafael Amado, Senior Vice President Oncology Development.  "We look forward to the results from ongoing clinical trials with lapatinib in different combinations and lines of therapy, including the adjuvant setting, to assess the optimal use of lapatinib in women with HER2 positive breast cancer."  

Lapatinib was first approved for use in combination therapy in the metastatic setting in 2007 and is currently approved in 107 countries including the U.S., Europe, Australia, India, Brazil, Russia, Turkey, South Korea and other countries around the world.  

About TEACH:  The TEACH trial (Tykerb Evaluation After CHemotherapy; EGF105485) is a Phase III,  randomised, double-blind, placebo-controlled, study of lapatinib versus placebo in women with HER2-positive breast cancer who have not been previously treated with trastuzumab.  Most (55%) of the patients did not receive treatment with trastuzumab because they had completed treatment before trastuzumab was available and it was not institutional practice to use trastuzumab in the delayed adjuvant setting.  22% of the women enrolled in TEACH did not have access to trastuzumab because it was not available in their country or investigative centre and the remaining women were not treated with trastuzumab due to other reasons, including patient preference/convenience.  HER2 status for study entry was initially determined by immunohistochemistry (IHC) testing or fluorescent in situ hybridization (FISH) at local laboratories or at a central laboratory if HER2 status was unknown locally.  All patients' HER2 status was subsequently evaluated at a central laboratory using FISH.  The primary objective was to compare disease-free survival (DFS) between women treated with lapatinib and those treated with placebo in the early and delayed adjuvant treatment settings in a unique patient population.  TEACH was conducted in collaboration with Massachusetts General Hospital and more than 450 investigative centres in more than 30 countries participated in this study. 

About lapatinib (Tykerb or Tyverb)

In Europe, lapatinib, in combination with an aromatase inhibitor (AI), is indicated for the treatment of post-menopausal women with hormone receptor (HR)-positive, HER2 (ErbB2) over-expressing metastatic breast cancer and for whom chemotherapy is currently not intended.  In Europe, lapatinib is also approved in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumours over-express HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.  

In the United States, lapatinib is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that over-expresses the HER2 receptor for whom hormonal therapy is indicated.  Lapatinib in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.  Lapatinib is also FDA approved in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumours over-express HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.  

US FDA boxed warning and important safety information for Tykerb

Hepatotoxicity has been observed in clinical trials and post marketing experience.  The hepatotoxicity may be severe and deaths have been reported.  Causality of the deaths is uncertain.  Patients with known severe hypersensitivity to TYKERB or any of its components should not take TYKERB.  Also, patients may experience decreased left ventricular ejection fraction, hepatotoxicity, diarrhoea, interstitial lung disease/pneumonitis, QT prolongation, and risk of fetal harm in pregnant women.  If TYKERB is to be administered to patients with severe hepatic impairment, dose reduction should be considered.  The most common adverse reactions during therapy with TYKERB plus letrozole compared to letrozole were diarrhoea, rash, nausea, and fatigue.  The most common adverse reactions during therapy with TYKERB plus capecitabine versus capecitabine alone were diarrhoea, palmar-plantar erythrodysesthesia, nausea, rash, vomiting, and fatigue.  

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

Stephen Rea

+44 (0) 20 8047 5502

(London)

Sarah Spencer

+44 (0) 20 8047 5502

(London)

David Daley

+44 (0) 20 8047 5502

(London)

US Media enquiries:

Kevin Colgan

+1 919 483 2839

(North Carolina)

Mary Anne Rhyne

+1 919 483 2839

(North Carolina)

Sarah Alspach

+1 919 483 2839

(Washington, DC)

Jennifer Armstrong

+1 919 483 2839

(Philadelphia)

Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543

(London)

Tom Curry

+ 1 215 751 5419

(Philadelphia)

Gary Davies

+ 44 (0) 20 8047 5503

(London)

Ziba Shamsi

+ 44 (0) 20 8047 3289

(London)

Jeff McLaughlin

+ 1 215 751 7002

(Philadelphia)

GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2010.



share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
02/22GLAXOSMITHKLINE : Ex-dividend day for for final dividend
FA
02/21GLAXOSMITHKLINE : recalls Ventolin Diskus inhalers
AQ
02/20GLAXOSMITHKLINE PLC : Today’s Research Reports on Trending Tickers: GlaxoSmithKl..
AC
02/16GLAXOSMITHKLINE : GSK submits landmark IMPACT data to European Medicines Agency ..
AQ
02/15GLAXOSMITHKLINE : Details Findings in Organic Research [High-Throughput Automate..
AQ
02/15GLAXOSMITHKLINE : An Application for the Trademark "ELEBRATO" Has Been Filed by ..
AQ
02/15FINDINGS FROM GLAXOSMITHKLINE PLC IN : Efficacy,...
AQ
02/15GLAXOSMITHKLINE : Reports from GlaxoSmithKline plc Provide New Insights into Bio..
AQ
02/15GLAXOSMITHKLINE : Investigators at GlaxoSmithKline plc Release New Data on Monoc..
AQ
02/15GLAXOSMITHKLINE : New Whooping Cough Study Results from GlaxoSmithKline plc Desc..
AQ
More news
News from SeekingAlpha
02/21Tracking Tweedy Browne Portfolio - Q4 2017 Update 
02/21CytoDyn Makes Huge Stride For HIV Patients, Now Acts As A Potential Acquisiti.. 
02/21GlaxoSmithKline goes ex-dividend tomorrow 
02/20FDA tentatively OKs Mylan's HIV combo pill 
02/20AGENUS : Positioned To Rapidly Enhance Shareholder Value 
Financials ( GBP)
Sales 2018 30 206 M
EBIT 2018 8 317 M
Net income 2018 4 101 M
Debt 2018 13 333 M
Yield 2018 6,04%
P/E ratio 2018 15,34
P/E ratio 2019 13,94
EV / Sales 2018 2,62x
EV / Sales 2019 2,53x
Capitalization 65 676 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 15,3  GBP
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE0.16%91 180
JOHNSON & JOHNSON-6.33%349 006
NOVARTIS-2.67%224 221
PFIZER-0.58%213 155
ROCHE HOLDING LTD.-9.33%206 183
MERCK AND COMPANY-2.29%148 618